Osteopore Ltd (osx) Logo

Osteopore Ltd (OSX)

___:___ · Healthcare

OSX Chart


OSX's Principal Activity is the medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. It also fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -56.61%
vs ASX 200 (1yr) -64.50%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,745 of 2,413
Sector Rank 158 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies TRU / EX1 / AMT
EPS -$0.031
DPS $0.00
Book Value Per Share $0.05

Broker Consensus

OSX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Osteopore Limited (OSX) is an Australian and Singapore based medical technology company commercialising a range of products engineered to facilitate bone healing across range of therapeutic areas. The Group's patented technology fabricates micro-structured scaffolds for bone regeneration through 3D printing & bioresorbable material, bioresorbable scaffolds for regenerative bone healing.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office West Perth WA 6005
Website www.osteopore.com
Registry Link Market Services
Auditor Grant Thornton Audit Pty Ltd
Date Listed 23 Sep 2019

Upcoming Calendar (Forecasted)

Date Event
31/05/2022 AGM
30/08/2022 Report (Interim)
27/02/2023 Report (Prelim)
30/03/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Daniel Ow Non-Executive Director Oct 2021

Mr Daniel Ow

Non-Executive Director

Mr Ow has over twenty years' international experience across multiple industries, including infrastructure, resources, property and fast-moving consumer goods.

Mr Mark Leong Executive Chairman,Executive Director Aug 2021

Mr Mark Leong

Executive Chairman,Executive Director

Mr Leong has more than 22 years of corporate, management and directorship experience in a broad range of functions in a diverse range of industries having undertaken several C-suite roles (CEO, COO, & CFO) in several private as well as listed companies and presently serves as Independent Director in 3 Singapore listed companies.

Professor Swee Hin Teoh Non-Executive Director Jun 2019

Professor Swee Hin Teoh

Non-Executive Director

Prof Teoh is the President's Chair, School of Chemical and Biomedical Engineering (SCBE). He holds a joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University. His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. Majoring in Materials Engineering (B. Eng - 1st Class Hon and PhD, Monash University), his research journey focused on translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechno induction through load bearing scaffolds for tissue regeneration and remodelling. Prof. Teoh's work on 3D printed scaffold led to him receiving the prestigious "Golden Innovation Award" at the Far East Economic Review, and the Institute of Engineers "Prestigious Engineering Achievement Award" in 2004. His group was ranked 1st in bone tissue engineering scaffolds in World Web of Science 2010. He was honoured with the Special Award for "Scientific Life-Time Achievement in Bone Tissue Engineering" at Bone-Tec 2015, Stuttgart. As a part of SG50 celebrations, he was featured as one of Singapore's profiled scientists in the book titled Singapore's Scientific Pioneers. Prof. Teoh is presently the Chairman, Singapore Academy, Asia Regulatory Professional Association (ARPA). He sits in as board of editors Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Journal of Mechanical Behaviour of Biomedical Materials, Journal of Oral & Maxillofacial Research and Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine.

Mr Khoon Seng Goh Chief Executive Officer Sep 2018

Mr Khoon Seng Goh

Chief Executive Officer

Mr Goh has 30-year career spans both start-ups and global multinational corporations, with responsibilities in research and development, manufacturing, regional sales and marketing, and country management. Prior to joining Osteopore Mr Goh spent over 20 years with Medtronic plc (Medtronic plc is the world's largest medical device company) and Edwards Lifesciences Asia in various senior management roles. Mr Goh has been a Director of Osteopore Pte Ltd, since 2015 and has been involved in all aspects of the Company.

Ms Deborah Ho Company Secretary N/A

Director Transactions

OSX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
18/02/22 Swee Hin Teoh Transfer 7,030,309 $0.21 $1,476,364 As advised by the company
18/02/22 Swee Hin Teoh Transfer 7,030,309 $0.21 $1,476,364 As advised by the company

Director Interests

The current holdings of OSX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Swee Hin Teoh 18/02/2022 0 7,030,309 1,500,000 N/A
Daniel Ow 07/10/2021 0 N/A N/A N/A
Mark Leong 01/08/2021 0 N/A N/A N/A
Khoon Seng Goh N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Mar 25, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Citicorp Nominees Pty Limited 21,662,055 18.47%
Mr Michael Marcus Liew 15,662,862 13.36%
Mr Patrick John Mchale 7,248,150 6.18%
BNP Paribas Noms Pty Ltd 6,126,311 5.22%
HSBC Custody Nominees (Australia) Limited 4,852,854 4.14%
Ching-Yuan Huang 4,211,529 3.59%
Lim Thiam Chye 3,676,740 3.14%
Ho-Chwan Investment Co Ltd 3,158,647 2.69%
Mr Hanry Yu 3,155,552 2.69%
Mr Lim Jing 2,360,000 2.01%
Dietmar Hutmacher 2,213,500 1.89%
Annika Walter Schantz 2,097,000 1.79%
Round Table Partners Berhad 1,534,500 1.31%
Dr Russell Kay Hancock 1,500,000 1.28%
BNP Paribas Noms Pty Ltd I 1,225,698 1.05%
Tan Siow Khoon 1,223,250 1.04%
Mr Evan Philip Clucas & Ms Leanne Jane Weston 981,351 0.84%
Celery Pty Ltd 966,279 0.82%
Mr Frankie Wei Seng Lee 938,500 0.80%
Sbv Capital Pty Ltd 875,000 0.75%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 380 807 371 478 67 2,103

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Citicorp Nominees Pty Limited 25/03/2022 21,662,055 18.47

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
13-07-21 The Rain Maker MGMT SDN BHD 3,032,582 11.3 8.76

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.46 30 June
2020 $0.40 30 June
OSX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.